Skip to main content
. 2023 Nov 27;13:1294801. doi: 10.3389/fcimb.2023.1294801

Figure 2.

Figure 2

Selection of a pair of anti-PirA and anti-PirB scFvs for developing an immunoassay. (A) CDR-H3 sequence and frequency of anti-PirA and anti-PirB scFv clones. Four anti-PirA scFvs (1B3, 1A8, 1C10, and 2C4) and two anti-PirB scFvs (3G7 and 3A5) were identified after sequencing analysis, and the frequency of each scFv antibody was determined. (B, C) Validation of binding activity of scFv clones. Each scFv with 6xHis tag was purified by Ni-NTA column and was titrated to assess the binding activity to (B) PirA, or (C) PirB by ELISA.